The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Navigating the complexity of percutaneous coronary intervention in patients at high risk for bleeding

EuroIntervention 2018;14:e383-e385 published online e-edition July 2018. DOI: 10.4244/EIJV14I4A68

The Zena and Michael A. Wiener Cardiovascular Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, USA

The co-evolution of coronary stent technologies and antithrombotic pharmacotherapies has been driven by the delicate balance of two opposing forces: bleeding and thrombosis1. The pathophysiological rationale of antithrombotic therapies after coronary stent implantation is predicated on the need to protect the stented vascular segment from device thrombosis while stent endothelialisation is ongoing2. However, all antithrombotic agents are associated with increased risk for bleeding, the magnitude of which is proportional to their intensity and time of exposure2. Compared with bare metal stents (BMS), early-generation drug-eluting stents (DES) required prolonged periods of dual antiplatelet therapy (DAPT) due to high rates of ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
What is new in the armamentarium of coronary surgeons to compete with PCI?